By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

AzurRx BioPharma 

760 Parkside Avenue
Downstate Biotechnology Incubator, Suite 217
Brooklyn  New York  11226  U.S.A.
Phone: 646-699-7855 Fax: n/a


SEARCH JOBS

AzurRx BioPharma, Inc. aims to become a leader in developing non-systemic, recombinant protein therapies for the treatment of gastrointestinal diseases and related conditions. MS1819 recombinant lipase for exocrine pancreatic insufficiency is the company’s lead development program, and additional early stage research is being conducted for the prevention of hospital-acquired infection. The company is headquartered in Brooklyn, NY, with scientific operations based in Langlade, France.

LEADERSHIP:

CEO: Thijs Spoor

CSO: Daniel Dupret

CLINICAL TRIAL:

Please click here for clinical trial information.


Key Statistics


Email: info@azurrx.com
Ownership: Public

Web Site: AzurRx BioPharma
Employees:
Symbol: AZRX
 









Company News
AzurRx BioPharma (AZRX) Announces Addition Of Charles J Casamento To The Board Of Directors 3/8/2017 8:28:21 AM
AzurRx BioPharma (AZRX) Announces First Three Patients Included In Phase Ila Study With MS1819-SD For Endocrine Pancreatic Insufficiency 12/21/2016 9:16:29 AM
AzurRx BioPharma (AZRX) Announces Agreement In Principle With Transchem For MTAN Inhibition Technology 12/6/2016 7:49:52 AM
AzurRx BioPharma (AZRX) CEO Provides Shareholders With A "State Of The Union" Communication 12/1/2016 7:24:41 AM
AzurRx BioPharma (AZRX) And Mayoly Spindler Announce Initiation Of Phase II Clinical Trial Of MS1819-SD For Exocrine Pancreatic Insufficiency In Chronic Pancreatitis Patients 11/17/2016 7:45:55 AM
AzurRx BioPharma (AZRX) Announces Pricing Of Initial Public Offering 10/12/2016 11:16:35 AM
//-->